Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorBUTLER, Javed
dc.contributor.authorFILIPPATOS, Gerasimos
dc.contributor.authorSIDDIQI, Tariq Jamal
dc.contributor.authorFERREIRA, Joao Pedro
dc.contributor.authorBRUECKMANN, Martina
dc.contributor.authorBOCCHI, Edimar
dc.contributor.authorBOHM, Michael
dc.contributor.authorCHOPRA, Vijay K.
dc.contributor.authorGIANNETTI, Nadia
dc.contributor.authorIWATA, Tomoko
dc.contributor.authorJANUZZI, James L.
dc.contributor.authorKAUL, Sanjay
dc.contributor.authorPINA, Ileana L.
dc.contributor.authorPONIKOWSKI, Piotr
dc.contributor.authorRAUCH-KROHNERT, Ursula
dc.contributor.authorSHAH, Sanjiv J.
dc.contributor.authorSENNI, Michele
dc.contributor.authorSUMIN, Mikhail
dc.contributor.authorVERMA, Subodh
dc.contributor.authorZHANG, Jian
dc.contributor.authorPOCOCK, Stuart J.
dc.contributor.authorZANNAD, Faiez
dc.contributor.authorPACKER, Milton
dc.contributor.authorANKER, Stefan D.
dc.date.accessioned2022-12-21T13:19:22Z
dc.date.available2022-12-21T13:19:22Z
dc.date.issued2022
dc.description.abstractBackground: Women and men with heart failure (HF) and preserved ejection fraction may differ in their clinical characteristics and their response to therapy. The aim of this study was to evaluate the influence of sex on the effects of empagliflozin in patients with HF and preserved ejection fraction enrolled in the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction). Methods: The effects of empagliflozin on the primary outcome of cardiovascular death or hospitalization for HF and on secondary outcomes (including total HF hospitalization, cardiovascular and all-cause mortality, and Kansas City Cardiomyopathy Questionnaire scores) were compared in women and men in the overall cohort and in subgroups defined by left ventricular ejection fraction (41%-49%, 50%-59%, and & GE;60%). The effects of empagliflozin on physiological measures, including changes in systolic blood pressure, uric acid, hemoglobin, body weight, and natriuretic peptide levels, were also assessed. Results: Of the 5988 patients randomized, 2676 (44.7%) were women. In the placebo arm, women tended to have lower risk for adverse outcomes, including a lower risk of all-cause mortality (hazard ratio, 0.69 [95% CI, 0.56, 0.84]). Compared with placebo, empagliflozin reduced the risk of cardiovascular death or hospitalization for HF to a similar degree in both sexes (hazard ratio, 0.81 [95% CI, 0.69, 0.96] for men; and hazard ratio, 0.75 [95% CI, 0.61, 0.92] for women; P-interaction=0.54). Sex did not modify the relationship between empagliflozin and outcomes across ejection fraction groups. Similar results were seen for secondary outcomes and physiological measures. Compared with placebo, empagliflozin improved the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score to a similar extent in both sexes (1.38 for men versus 1.63 for women at 52 weeks; P-interaction=0.77); the results were similar for Kansas City Cardiomyopathy Questionnaire overall summary score and total summary score. Conclusions: Empagliflozin produced similar benefits on outcomes and health status in women and men with HF and preserved ejection fraction.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipBoehringer Ingelheim
dc.description.sponsorshipEli Lilly
dc.description.sponsorshipCompany Diabetes Alliance
dc.identifier.citationCIRCULATION, v.146, n.14, p.1046-1055, 2022
dc.identifier.doi10.1161/CIRCULATIONAHA.122.059755
dc.identifier.eissn1524-4539
dc.identifier.issn0009-7322
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/50467
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINSeng
dc.relation.ispartofCirculation
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINSeng
dc.subjectempagliflozineng
dc.subjecthealth statuseng
dc.subjectheart failureeng
dc.subjecthospitalizationeng
dc.subjectmeneng
dc.subjectwomeneng
dc.subject.othersex-differenceseng
dc.subject.otherclinical characteristicseng
dc.subject.othercandesartaneng
dc.subject.otherreductioneng
dc.subject.othermortalityeng
dc.subject.otherspectrumeng
dc.subject.otheroutcomeseng
dc.subject.wosCardiac & Cardiovascular Systemseng
dc.subject.wosPeripheral Vascular Diseaseeng
dc.titleEffects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fractioneng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryGrécia
hcfmusp.affiliation.countryPortugal
hcfmusp.affiliation.countryAlemanha
hcfmusp.affiliation.countryÍndia
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryPolônia
hcfmusp.affiliation.countryItália
hcfmusp.affiliation.countryChina
hcfmusp.affiliation.countryInglaterra
hcfmusp.affiliation.countryFrança
hcfmusp.affiliation.countryisode
hcfmusp.affiliation.countryisoca
hcfmusp.affiliation.countryisocn
hcfmusp.affiliation.countryisogb
hcfmusp.affiliation.countryisofr
hcfmusp.affiliation.countryisous
hcfmusp.affiliation.countryisogr
hcfmusp.affiliation.countryisopt
hcfmusp.affiliation.countryisoin
hcfmusp.affiliation.countryisopl
hcfmusp.affiliation.countryisoit
hcfmusp.author.externalBUTLER, Javed:Univ Mississippi, Dept Med, Sch Med, Jackson, MS 39216 USA; Baylor Scott & White Res Inst, Dallas, TX USA
hcfmusp.author.externalFILIPPATOS, Gerasimos:Natl & Kapodistrian Univ Athens, Athens Univ Hosp Attikon, Sch Med, Athens, Greece
hcfmusp.author.externalSIDDIQI, Tariq Jamal:Univ Mississippi, Dept Med, Sch Med, Jackson, MS 39216 USA
hcfmusp.author.externalFERREIRA, Joao Pedro:Univ Lorraine, Ctr Invest Clin, INSERM, Nancy, France; CHRU, F CRIN INI CRCT Cardiovasc & Renal Clin Trialists, Inserm U1116, Nancy, France; Univ Porto, Cardiovasc Res & Dev Ctr, Dept Surg & Physiol, Fac Med, Porto, Portugal
hcfmusp.author.externalBRUECKMANN, Martina:Boehringer Ingelheim Int GmbH, Ingelheim, Germany; Heidelberg Univ, Fac Med Mannheim, Dept Med 1, Mannheim, Germany
hcfmusp.author.externalBOHM, Michael:Saarland Univ, Univ Klinikum Saarlandes, Klin Innere Med 3, Homburg, Germany
hcfmusp.author.externalCHOPRA, Vijay K.:Max Superspecial Hosp, New Delhi, India
hcfmusp.author.externalGIANNETTI, Nadia:McGill Univ, Div Cardiol, Hlth Ctr, Montreal, PQ, Canada
hcfmusp.author.externalIWATA, Tomoko:Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
hcfmusp.author.externalJANUZZI, James L.:Massachusetts Gen Hosp, Boston, MA 02114 USA; Baim Inst Clin Res, Boston, MA USA
hcfmusp.author.externalKAUL, Sanjay:Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
hcfmusp.author.externalPINA, Ileana L.:Cent Michigan Univ, Mt Pleasant, MI 48859 USA
hcfmusp.author.externalPONIKOWSKI, Piotr:Wroclaw Med Univ, Wroclaw, Poland
hcfmusp.author.externalRAUCH-KROHNERT, Ursula:Charite Univ Med Berlin, Dept Cardiol, Campus Benjamin Franklin, Berlin, Germany; German Ctr Cardiovasc Res, Partner Site Berlin, Berlin, Germany
hcfmusp.author.externalSHAH, Sanjiv J.:Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
hcfmusp.author.externalSENNI, Michele:Papa Giovanni XXIII Hosp, Cardiovasc Dept, Cardiol Div, Bergamo, Italy
hcfmusp.author.externalSUMIN, Mikhail:Boehringer Ingelheim Int GmbH, Ingelheim, Germany
hcfmusp.author.externalVERMA, Subodh:Univ Toronto, Div Cardiac Surg, St Michaels Hosp, Toronto, ON, Canada
hcfmusp.author.externalZHANG, Jian:Chinese Acad Med Sci, Fuwai Hosp, Beijing, Peoples R China
hcfmusp.author.externalPOCOCK, Stuart J.:London Sch Hyg & Trop Med, Dept Med Stat, London, England
hcfmusp.author.externalZANNAD, Faiez:Univ Lorraine, Ctr Invest Clin, INSERM, Nancy, France; CHRU, F CRIN INI CRCT Cardiovasc & Renal Clin Trialists, Inserm U1116, Nancy, France
hcfmusp.author.externalPACKER, Milton:Baylor Univ, Med Ctr, Baylor Heart & Vasc Inst, Dallas, TX USA; Imperial Coll, London, England
hcfmusp.author.externalANKER, Stefan D.:German Ctr Cardiovasc Res, Partner Site Berlin, Berlin, Germany; Dept Cardiol, Berlin, Germany; Berlin Inst Hlth Ctr Regenerat & Herapies, Berlin, Germany; Charite Univ Med Berlin, Berlin, Germany
hcfmusp.citation.scopus22
hcfmusp.contributor.author-fmusphcEDIMAR ALCIDES BOCCHI
hcfmusp.description.beginpage1046
hcfmusp.description.endpage1055
hcfmusp.description.issue14
hcfmusp.description.volume146
hcfmusp.origemWOS
hcfmusp.origem.pubmed36098051
hcfmusp.origem.scopus2-s2.0-85139571301
hcfmusp.origem.wosWOS:000886562300003
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAnker SD, 2019, EUR J HEART FAIL, V21, P1279, DOI 10.1002/ejhf.1596eng
hcfmusp.relation.referenceBeale AL, 2019, JACC-HEART FAIL, V7, P239, DOI 10.1016/j.jchf.2019.01.004eng
hcfmusp.relation.referenceBoehringer Ingelheim, DAT DOC SHAReng
hcfmusp.relation.referenceBorlaug BA, 2011, CIRCULATION, V123, P2006, DOI 10.1161/CIRCULATIONAHA.110.954388eng
hcfmusp.relation.referenceButler J, 2022, EUR HEART J, V43, P416, DOI 10.1093/eurheartj/ehab798eng
hcfmusp.relation.referenceCenter for Global Clinical Research Data, VIVLeng
hcfmusp.relation.referenceCleland JGF, 2006, EUR HEART J, V27, P2338, DOI 10.1093/eurheartj/ehl250eng
hcfmusp.relation.referenceDewan P, 2020, EUR J HEART FAIL, V22, P898, DOI 10.1002/ejhf.1776eng
hcfmusp.relation.referenceGori M, 2014, EUR J HEART FAIL, V16, P535, DOI 10.1002/ejhf.67eng
hcfmusp.relation.referenceLam CSP, 2012, CIRC-HEART FAIL, V5, P571, DOI 10.1161/CIRCHEARTFAILURE.112.970061eng
hcfmusp.relation.referenceMcMurray JJV, 2020, CIRCULATION, V141, P338, DOI 10.1161/CIRCULATIONAHA.119.044491eng
hcfmusp.relation.referenceMerrill M, 2019, JACC-HEART FAIL, V7, P228, DOI 10.1016/j.jchf.2019.01.003eng
hcfmusp.relation.referenceO'Meara E, 2007, CIRCULATION, V115, P3111, DOI 10.1161/CIRCULATIONAHA.106.673442eng
hcfmusp.relation.referencePacker M, 2020, EUR J HEART FAIL, V22, P1551, DOI 10.1002/ejhf.1902eng
hcfmusp.relation.referenceSantos-Gallego CG, 2021, J AM COLL CARDIOL, V77, P243, DOI 10.1016/j.jacc.2020.11.008eng
hcfmusp.relation.referenceScantlebury DC, 2011, CURR OPIN CARDIOL, V26, P562, DOI 10.1097/HCO.0b013e32834b7fafeng
hcfmusp.relation.referenceStolfo D, 2019, JACC-HEART FAIL, V7, P505, DOI 10.1016/j.jchf.2019.03.011eng
hcfmusp.relation.referenceYoung JB, 2004, CIRCULATION, V110, P2618, DOI 10.1161/01.CIR.0000146819.43235.A9eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationb91a2818-f913-410b-afa2-af089f99e39c
relation.isAuthorOfPublication.latestForDiscoveryb91a2818-f913-410b-afa2-af089f99e39c
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_BUTLER_Effects_of_Empagliflozin_in_Women_and_Men_With_2022.PDF
Tamanho:
1.01 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - ODS/03